Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Head & Neck 1Genitourinary 1

Conditions

Neoplasms 4Carcinoma, Transitional Cell 3Urinary Bladder Neoplasms 2Neoplasm Metastasis 2Head and Neck Neoplasms 2Small Cell Lung Carcinoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Breast Cancer Metastatic 1Adenocarcinoma of Lung 1Acrocephalosyndactylia 1

Interventions

Gemcitabine 74Capecitabine 60Paclitaxel 59Fluorouracil 58Oxaliplatin 57Bevacizumab 51Docetaxel 50Leucovorin 48Nivolumab 40Cisplatin 40Irinotecan 39Carboplatin 37Cetuximab 34pembrolizumab 32Radiosurgery 32Trastuzumab 30Radiotherapy 27Everolimus 24Sorafenib 23Pemetrexed 20Doxorubicin 20Albumin-Bound Paclitaxel 20Ipilimumab 19Cyclophosphamide 19Panitumumab 18Zoledronic Acid 17Lapatinib 17Erlotinib Hydrochloride 17Prednisone 16pazopanib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Neoplasm Metastasis × Rogaratinib × Clear all
NCT03517956 2022-07-14

ROCOCO

Bayer

Phase 1 Completed
16 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01976741 2021-05-06

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Bayer

Phase 1 Completed
168 enrolled 59 charts
GenitourinaryHead & NeckThoracic

Adenocarcinoma of Lung, Urinary Bladder Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡